VICT3R Developing and implementing VIrtual Control groups To reducE animal use in toxicology Research
- Coordinator
- Universidad Pompeu Fabra, Spain
- Runs
- 1 September 2024 to 29 February 2028
- Status
- Running
- EU funding
- €13.5m
- Total cost
- €27.0m
- Partners
- 45 organisations in 13 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101172693
What the project is doing
In the project's own words, from its summary on CORDIS.
VICT3R, a public-private partnership running under the European Innovative Health Initiative, aims to significantly reduce the number of animals used in experimental studies performed during the nonclinical drug and chemical safety evaluation by replacing the animals of the concurrent controls groups (CCGs) with Virtual Control Groups (VCGs). These VCGs will be generated by means of state-of-the-art statistical or artificial intelligence (AI) approaches that optimally exploit the wealth of historical data from control animals accumulated over decades by pharmaceutical companies and other relevant industrial and academic sectors.
The VCG concept was conceived and prototyped during the recently finished eTRANSAFE IMI2 project for its application in the nonclinical safety assessment of the pharmaceutical industry. A preliminary evaluation of the VCG concept carried out in the eTRANSAFE project demonstrated that it is generally feasible, yet scientifically and operationally challenging and must therefore be refined before its adoption for regulatory hazard and risk assessment.
The main challenges consist of adequate data collection and curation, identification of key variables to achieve optimal matching between VCGs and CCGs, and validation of procedures including compliance with Good Laboratory Practice (GLP). These challenges will be systematically tackled in VICT3R for achieving the full development and regulatory acceptance of the VCG concept. VICT3R will collect, curate and analyse large data sets of control animals from different species to produce a large high-quality database.
The database will be made available to VICT3R partners, regulators, and policy makers with the purpose to allow maturation of the VCG concept and to prove its validity, reproducibility and robustness. While VICT3R will be primarily focused on repeated dose toxicity studies, the extension of the VCG concept to other types of studies involving animals will also be tackled. VICT3R will promote that its database and software platform is maintained and expanded long term.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universidad Pompeu Fabra | Barcelona | Spain | Coordinator |
| Janssen Pharmaceutica NV | Beerse | Belgium | Participant |
| Ucb Biopharma | Bruxelles / Brussel | Belgium | Participant |
| Vrije Universiteit Brussel | Bruxelles / Brussel | Belgium | Participant |
| Zoetis Belgium SA | Louvain La Neuve | Belgium | Participant |
| F. Hoffmann-La Roche AG | Basel | Switzerland | Participant |
| Novartis Pharma AG | Basel | Switzerland | Participant |
| Takeda Pharmaceuticals International AG | Glattpark | Switzerland | Participant |
| Amgen Research (munich) GmbH | Munchen | Germany | Participant |
| Basf Se | Ludwigshafen Am Rhein | Germany | Participant |
| Bayer Aktiengesellschaft | Leverkusen | Germany | Participant |
| Boehringer Ingelheim Internationalgmbh | Ingelheim | Germany | Participant |
| Boehringer Ingelheim Pharma GmbH &co Kg | Ingelheim | Germany | Associatedpartner |
| CAATevents gGmbH | Solingen | Germany | Participant |
| Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eV | Munchen | Germany | Participant |
| Merck Electronics Kgaa | Darmstadt | Germany | Associatedpartner |
| Merck Healthcare Kgaa | Darmstadt | Germany | Associatedpartner |
| Merck Kommanditgesellschaft Auf Aktien | Darmstadt | Germany | Participant |
| Merck Life Science Kgaa | Darmstadt | Germany | Associatedpartner |
| Sanofi-Aventis Deutschland GmbH | Frankfurt Am Main | Germany | Participant |
| Syncwork Aktiengesellschaft | Dresden | Germany | Participant |
| Technische Universitat Dortmund | Dortmund | Germany | Participant |
| Universitat Konstanz | Konstanz | Germany | Participant |
| Gritsystems AS | Valby | Denmark | Participant |
| Novo Nordisk A/s | Bagsvaerd | Denmark | Participant |
| Barcelona Supercomputing Center Centro Nacional De Supercomputacion | Barcelona | Spain | Participant |
| Medbioinformatics Solutions SL | Barcelona | Spain | Participant |
| Synapse Research Management Partners SL | Madrid | Spain | Participant |
| Orion Oyj | Espoo | Finland | Participant |
| Institut Servier De Medecine Translationnelle | Gif-Sur-Yvette | France | Participant |
| Ipsen Innovation SAS | Paris | France | Participant |
| Deciphex Limited | Mornington Meath | Ireland | Participant |
| Phuse Cuideachta Faoi Theorainn Rathaiochta | Dublin | Ireland | Participant |
| Istituto di Ricerche Biomediche Antoine Marxer RBM S.p.A. | Colleretto Giacosa | Italy | Associatedpartner |
| Incyte Biosciences Distribution B.v | Amsterdam | Netherlands | Participant |
| Janssen Vaccines & Prevention BV | Leiden | Netherlands | Associatedpartner |
| Organon SRL | Bucharest | Romania | Participant |
| Astrazeneca UK Limited | Cambridge | United Kingdom | Participant |
| Glaxosmithkline Research & Development Limited | London | United Kingdom | Participant |
| Instem Scientific Limited | Stone Staffordshire | United Kingdom | Participant |
| Abbvie Inc | North Chicago Il | United States | Participant |
| Bristol-Myers Squibb Company Corp | New York | United States | Participant |
| Incyte Corporation | Wilmington | United States | Associatedpartner |
| Janssen Research & Development, LLC | Raritan | United States | Associatedpartner |
| Pfizer Inc | New York City | United States | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI